marketcaparena

NervGen Pharma Corp.

NGEN · Figures in Canadian dollars

About NervGen Pharma

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

nervgen.com ↗

Employees
9
Listed
Nasdaq · NGEN

Income statement

Revenue, gross profit and net income

Q1 26
Full year
Quarter
Revenue, gross profit and net income on one scale, so their sizes can be compared period by period.

Cash flow

Operating and free cash flow

Q1 26
Full year
Quarter
Free cash flow is what is left of operating cash flow after capital expenditure. The gap between each pair of bars is that year's capex.

Stock-based compensation

Q1 26
Full year
Quarter
Stock-based compensation reported in the cash flow statement each period. The line is that amount as a percentage of the same period's revenue.
Stock-based compensation